

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0105	
Drug name and formulations:	Latanoprost and Timolol preservative-free (Fixapost®)	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Equivalent to existing preparations
Clinical effectiveness	<i>Established licensed product</i>	Equivalent to existing preparations
Strength of evidence		Strong
Patient factors	<i>Published patient factors</i>	Prevalence of ocular surface disease increases with age
Cost effectiveness or resource impact	£	Cost effective compared to alternatives
Place of therapy relative to available treatments	<i>1/2nd tier</i>	3 rd line
National guidance and priorities	<i>NICE, MTRAC</i>	SMC approved in patients who have proven sensitivity to preservatives
Local health priorities	<i>CCG views</i>	CCGs Supportive
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	None required
Prescribing data	<i>Requires 12 months primary or secondary care data</i>	Preservative-free preparations are monitored by CCGs

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Amber Specialist Recommendation
Implementation requirements:	